Page 46 - 林口長庚醫研部電子報-2018年6月刊

NEWSLETTER JUNE 2018 要做就要做到最好 - 頂尖暨優秀論文介紹 NEWSLETTER JUNE 2018 要做就要做到最好 - 頂尖暨優秀論文介紹

IF ≧ 5 或該領域前 10% IF ≧ 5 或該領域前 10%

Stomatin-like protein 2 regulates survivin
Favorable versus unfavorable prognostic expression in non-small cell lung cancer
groups by post-chemoradiation FDG-PET imaging cells through beta-catenin signaling pathway
in node-positive esophageal squamous cell CELL DEATH & DISEASE, MAR. 2018
carcinoma patients treated with definitive IF= 5.965 (20.53%)

chemoradiotherapy
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND 第一 / 指導作者：胸腔內科楊政達醫師
MOLECULAR IMAGING, MAY. 2018

IF= 7.277 (2.38%) Hyperglycemia and risk of adverse outcomes
第一作者：放射腫瘤科葉永堅醫師 following microvascular reconstruction of
指導作者：放射腫瘤科洪宗民醫師 葉永堅醫師 oncologic head and neck defects

ORAL ONCOLOGY, APR. 2018
Serum irisin levels are associated with IF= 4.794 (1.11%)
adverse cardiovascular outcomes in patients 第一作者：整形外科高煌凱醫師

with acute myocardial infarction
INTERNATIONAL JOURNAL OF CARDIOLOGY, JUN.
2018
IF= 6.189 (12.7%) A Comparative Assessment of Implant Site

第一作者：心臟內科謝宜璋醫師 Viability in Humans and Rats
指導作者：心臟內科王朝永醫師 JOURNAL OF DENTAL RESEARCH, APR. 2018
IF= 4.755 (2.22%)

第一作者：整形外科陳志豪醫師
The effectiveness and safety of low-dose
rivaroxaban in Asians with non-valvular Pretreatment clinical stage predicts

atrial fibrillation locoregional recurrence in patients with
INTERNATIONAL JOURNAL OF CARDIOLOGY, JUN. esophageal cancer who achieved a complete
2018 clinical response to chemoradiotherapy
IF= 6.189 (12.7%) JOURNAL OF THORACIC AND CARDIOVASCULAR

第一作者：心臟內科李信賦醫師 詹益欣醫師 SURGERY, MAY. 2018
IF= 4.446(6.09%)

指導作者：胸腔外科趙盈凱醫師

Downregulation of lumican accelerates lung The effectiveness of a saline mouth rinse

cancer cell invasion through p120 catenin regimen and education programme on radiation-
CELL DEATH & DISEASE, MAR. 2018 induced oral mucositis and quality of life
IF= 5.965 (20.53%) in oral cavity cancer patients: A randomised

第一作者：胸腔內科楊政達醫師 controlled trial
EUROPEAN JOURNAL OF CANCER CARE, MAR. 2018
IF= 2.104 (8.62%)

第一作者：放射腫瘤科黃炳勝醫師

45 非經本刊及作者同意，請勿做任何形式之轉載 46